Genomic Testing For Treatment Planning For Early Breast Cancer

  Address - Slovenia

  Contact details - 565656565

  Tender notice no. - 76454545

  GT Ref Id - 99516117

  Document Type - Tender Notices

Description - Description: The genomic tests OncotypeDX and Mammaprint have demonstrated clinical utility of level 1 in adjuvant systemic treatment with endocrine therapy and without chemotherapy in phase 3 clinical studies (TailorX and Mindact).Based on the resul ts, both tests are included in the main international clinical guidelines. In the clinical guidelines of the National Comprehensive Cancer Network (NCCN), the tests are classified as level 1 clinical utility.In view of the above, the contracting authority is issuing a public procurement for the subject of the contract No. JN-0040/2024 for "Genomic testing for treatment planning of early breast cancer", in two lots, namely:Lot 1: Oncotype DX® tes

Gt Ref Id - 99516117

Deadline - Jan 17, 2025